Anna Romaguera

Anna Romaguera

Auto-generated profile, based on publicly available information

Anna Romaguera

FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
EPEdith Pomarol-Clotet
Edith Pomarol-Clotet
SASilvia Alonso-Lana
Silvia Alonso-Lana
NMNoemi Moro
Noemi Moro
SSSalvador Sarró
Salvador Sarró
MBMar C. Bonnin
Mar C. Bonnin
RSRaymond Salvador
Raymond Salvador
Background: Little is known about how functional imaging changes in bipolar disorder relate to different phases of the illness.Aims: To compare cognitive task activation in participants with bipolar disorder examined in different phases of illness.Method: Participants with bipolar disorder in mania (n= 38), depression (n= 38) and euthymia (n= 38), as well as healthy controls (n= 38), underwent functional magnetic resonance imaging during performance of the n-back working memory task. Activations and de-activations were compared between the bipolar subgroups and the controls, and among the bipolar subgroups. All participants were also entered into a linear mixed-effects model.Results: Compared with the controls, the mania and depression subgroups, but not the euthymia subgroup, showed reduced activation in the dorsolateral prefrontal cortex, the parietal cortex and other areas. Compared with the euthymia subgroup, the mania and depression subgroups showed hypoactivation in the parietal cortex. All three bipolar subgroups showed failure of de-activation in the ventromedial frontal cortex. Linear mixed-effects modelling revealed a further cluster of reduced activation in the left dorsolateral prefrontal cortex in the patients; this was significantly more marked in the mania than in the euthymia subgroup.Conclusions: Bipolar disorder is characterised by mood state-dependent hypoactivation in the parietal cortex. Reduced dorsolateral prefrontal activation is a further feature of mania and depression, which may improve partially in euthymia. Failure of de-activation in the medial frontal cortex shows trait-like characteristics.

1 August 2015 in Schizophrenia Research
Verified
Journal Article
Closed access
AVAlicia Valiente-Gómez
Alicia Valiente-Gómez
GMGisela Mezquida
Gisela Mezquida
ARAnna Romaguera
Anna Romaguera
IVIrene Vilardebò
Irene Vilardebò
HAHelena Andrés
Helena Andrés
MBMiquel Bernardo
Miquel Bernardo

1 January 2015 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
JFJ.M. Farré
J.M. Farré
Fernando Fernández-ArandaFernando Fernández-Aranda
Fernando Fernández-Aranda
Roser GraneroRoser Granero
Roser Granero
NAN. Aragay
N. Aragay
NMNúria Mallorquí-Bagué
Núria Mallorquí-Bagué
Susana Jiménez-MurciaSusana Jiménez-Murcia
Susana Jiménez-Murcia

9 August 2017 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
AAAna Lucia Arellano
Ana Lucia Arellano
EPEsther Papaseit
Esther Papaseit
ARAnna Romaguera
Anna Romaguera
MTMarta Torrens
Marta Torrens
MFMagi Farré
Magi Farré
Background & Objective: Cannabis is the most widely used illicit drug. The two most important natural cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The THC content of cannabis has been increasing during the last years and recently appeared in the market as a series of synthetic cannabinoids with potent agonist activity. Recreational users frequently combine cannabis with other drugs of abuse as alcohol, amphetamines and derivatives, nicotine and cocaine. In addition, these subjects can be taking medicines for acute and chronic medical conditions. The increasing use of medicinal cannabis for chronic pain and neurological and psychiatric disorders can produce potential interactions with medications used for the symptomatic treatment of these or other diseases. Conclusion: THC and CBD are metabolized mainly in the liver by cytochrome P-450 isoenzymes (mainly CYP2Cs and CYP3A4). In vitro studies indicate that THC and CBD both inhibit CYP1A1, 1A2 and 1B1 enzymes, and recent studies have indicated that CBD is also a potent inhibitor of CYP2C19 and CYP3A4. Both cannabinoids may interact with other medications metabolized by the same pathway or by inducers/inhibitors of the isoenzymes. Cannabis produces sedation, impairs psychomotor performance, and increases blood pressure and heart rate. Pharmacodynamic interactions with other sedatives can potentiate the central effects but can be decreased by psychostimulants. This review focuses on the interactions between cannabinoids and alcohol, other drugs of abuse, and prescription medicines.

8 March 2019 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
SASilvia Alonso‐Lana
Silvia Alonso‐Lana
NMNoemí Moro
Noemí Moro
PMPeter J. McKenna
Peter J. McKenna
SSSalvador Sarró
Salvador Sarró
ARAnna Romaguera
Anna Romaguera
EPEdith Pomarol-Clotet
Edith Pomarol-Clotet

3 May 2018 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
AMAna Moreno-Alcázar
Ana Moreno-Alcázar
BGBegoña Gonzalvo
Begoña Gonzalvo
Erick Jorge Canales-RodríguezErick Jorge Canales-Rodríguez
Erick Jorge Canales-Rodríguez
LBLaura Blanco
Laura Blanco
DBDiana Bachiller
Diana Bachiller
EPEdith Pomarol-Clotet
Edith Pomarol-Clotet
Background: Structural imaging studies of cannabis users have found evidence of both cortical and subcortical volume reductions, especially in cannabinoid receptor-rich regions such as the hippocampus and amygdala. However, the findings have not been consistent. In the present study, we examined a sample of adult heavy cannabis users without other substance abuse to determine whether long-term use is associated with brain structural changes, especially in the subcortical regions. Method: We compared the gray matter volume of 14 long-term, heavy cannabis users with non-using controls. To provide robust findings, we conducted two separate studies using two different MRI techniques. Each study used the same sample of cannabis users and a different control group, respectively. Both control groups were independent of each other. First, whole-brain voxel-based morphometry (VBM) was used to compare the cannabis users against 28 matched controls (HC1 group). Second, a volumetric analysis of subcortical regions was performed to assess differences between the cannabis users and a sample of 100 matched controls (HC2 group) obtained from a local database of healthy volunteers. Results: The VBM study revealed that, compared to the control group HC1, the cannabis users did not show cortical differences nor smaller volume in any subcortical structure but showed a cluster (p < 0.001) of larger GM volume in the basal ganglia, involving the caudate, putamen, pallidum, and nucleus accumbens, bilaterally. The subcortical volumetric analysis revealed that, compared to the control group HC2, the cannabis users showed significantly larger volumes in the putamen (p = 0.001) and pallidum (p = 0.0015). Subtle trends, only significant at the uncorrected level, were also found in the caudate (p = 0.05) and nucleus accumbens (p = 0.047). Conclusions: This study does not support previous findings of hippocampal and/or amygdala structural changes in long-term, heavy cannabis users. It does, however, provide evidence of basal ganglia volume increases.